Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209108617> ?p ?o ?g. }
- W3209108617 endingPage "200111" @default.
- W3209108617 startingPage "200111" @default.
- W3209108617 abstract "Hypertension (HT) prevalence, Uncontrolled Blood Pressure (UBP), morbidity and mortality are highest in Sub-Saharan Africa (SSA). Correlating pathophysiology of HT to pharmaco-therapy with antihypertensive drugs (AHD) may bring amelioration. Aims:To review peculiarities of HT in SSA, UBP causes, diagnostic modalities, AHD use, rationality and efficacy.14 published therapeutic audits in 4 SSA nations on Google Scholar or PUBMED, (total n = 6496 patients) were evaluated. Calcium Channel blockers (CCB) amlodipine, and thiazide diuretics (TD), hydrochlorothiazide (HCTZ) were the commonest AHD. Thiazide Like Diuretics (TLD) were underutilized. The % of patients on AHD were: 1 drug 5.4-55%; 2 drugs 37-82%; >/ = 3 drugs 6-50.3%. 2-drug combinations were: ACEI/ARB + TD (42%); CCB + TD (36.8%); ACEI + CCB (15.8%) of studies. Triple/quadruple therapy included Methyldopa (MTD) with ACEI + CCB or TD. The (%) attaining BP < 140/< 90 mmHg, ranged from 29 to 53.6%, median, 44%. The co-morbidities, range and median were: Diabetes Mellitus (DM): 9.8-64%, 19.2%; Chronic Kidney Disease (CKD): 5.7-7.5%, 6.9%, and Coronary artery Disease (CAD): 0.9-2.6%, 2.3%. ACEI + CCB ± TD were the preferred AHD for comorbidities.Therapeutic inertia; Non-compliance; co-morbidities; refractory HT; ignorance; substandard AHD; contribute to UBP. Studies relating 24 hour ABPM to complications and mortality in SSA hypertensives; and impact of different AHD classes on ABPM, are needed. Study of ACEI + alpha-1 blockers + TLD on 24 hour ABPM and personalized care, are required." @default.
- W3209108617 created "2021-11-08" @default.
- W3209108617 creator A5015666712 @default.
- W3209108617 creator A5033147070 @default.
- W3209108617 date "2021-12-01" @default.
- W3209108617 modified "2023-09-27" @default.
- W3209108617 title "Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations – A review" @default.
- W3209108617 cites W123411394 @default.
- W3209108617 cites W1480198996 @default.
- W3209108617 cites W1573110643 @default.
- W3209108617 cites W1927589949 @default.
- W3209108617 cites W1964860017 @default.
- W3209108617 cites W1965084047 @default.
- W3209108617 cites W1972976017 @default.
- W3209108617 cites W1977480665 @default.
- W3209108617 cites W1978508573 @default.
- W3209108617 cites W1980376302 @default.
- W3209108617 cites W1982234569 @default.
- W3209108617 cites W1991803784 @default.
- W3209108617 cites W1998681689 @default.
- W3209108617 cites W1998880153 @default.
- W3209108617 cites W1999062633 @default.
- W3209108617 cites W2004283873 @default.
- W3209108617 cites W2007497901 @default.
- W3209108617 cites W2008821347 @default.
- W3209108617 cites W2016156579 @default.
- W3209108617 cites W2016490498 @default.
- W3209108617 cites W2024298544 @default.
- W3209108617 cites W2036099273 @default.
- W3209108617 cites W2036992162 @default.
- W3209108617 cites W2037945668 @default.
- W3209108617 cites W2042478264 @default.
- W3209108617 cites W2042545113 @default.
- W3209108617 cites W2043596618 @default.
- W3209108617 cites W2049952835 @default.
- W3209108617 cites W2051627076 @default.
- W3209108617 cites W2058147961 @default.
- W3209108617 cites W2062846313 @default.
- W3209108617 cites W2065639036 @default.
- W3209108617 cites W2068774543 @default.
- W3209108617 cites W2070797094 @default.
- W3209108617 cites W2071626971 @default.
- W3209108617 cites W2082426923 @default.
- W3209108617 cites W2095193515 @default.
- W3209108617 cites W2104577169 @default.
- W3209108617 cites W2108790161 @default.
- W3209108617 cites W2110052313 @default.
- W3209108617 cites W2126125759 @default.
- W3209108617 cites W2138996532 @default.
- W3209108617 cites W2140854783 @default.
- W3209108617 cites W2142461254 @default.
- W3209108617 cites W2207395446 @default.
- W3209108617 cites W2318760012 @default.
- W3209108617 cites W2321430508 @default.
- W3209108617 cites W2331364826 @default.
- W3209108617 cites W2335166645 @default.
- W3209108617 cites W2341473395 @default.
- W3209108617 cites W2395503415 @default.
- W3209108617 cites W2395581626 @default.
- W3209108617 cites W2410021471 @default.
- W3209108617 cites W2410396107 @default.
- W3209108617 cites W2413287085 @default.
- W3209108617 cites W2414281355 @default.
- W3209108617 cites W2418561582 @default.
- W3209108617 cites W2504981678 @default.
- W3209108617 cites W2511980545 @default.
- W3209108617 cites W2562304215 @default.
- W3209108617 cites W2571432806 @default.
- W3209108617 cites W2589250680 @default.
- W3209108617 cites W2600183113 @default.
- W3209108617 cites W2610627331 @default.
- W3209108617 cites W2657424181 @default.
- W3209108617 cites W2728405236 @default.
- W3209108617 cites W2745584358 @default.
- W3209108617 cites W2748143134 @default.
- W3209108617 cites W2749134413 @default.
- W3209108617 cites W2750131130 @default.
- W3209108617 cites W2788733594 @default.
- W3209108617 cites W2791588355 @default.
- W3209108617 cites W2799656662 @default.
- W3209108617 cites W2799837895 @default.
- W3209108617 cites W2834387971 @default.
- W3209108617 cites W2885567967 @default.
- W3209108617 cites W2887605153 @default.
- W3209108617 cites W2898115348 @default.
- W3209108617 cites W2913508783 @default.
- W3209108617 cites W2921088896 @default.
- W3209108617 cites W2953340620 @default.
- W3209108617 cites W2962471769 @default.
- W3209108617 cites W2963977772 @default.
- W3209108617 cites W2968003786 @default.
- W3209108617 cites W2968332922 @default.
- W3209108617 cites W2981695197 @default.
- W3209108617 cites W3011128887 @default.
- W3209108617 cites W3013905258 @default.
- W3209108617 cites W3025069099 @default.
- W3209108617 cites W3036500066 @default.
- W3209108617 cites W3081321041 @default.